🟢 Altimmune is trading 7.6% up in pre-market as its cause remains unclear

Altimmune is trading at $2.34, up 7.64%, with no confirmed catalyst for its October 23 pre-market move.

• No fresh company announcement explaining the move was identified; its latest listed release, dated October 19, concerned planned research presentations at AASLD.
• Positive RECLAIM Phase 2 results are older news, not a confirmed new catalyst.
• Major indices were modestly lower pre-market, so broader market strength does not explain the gain.